Toll-like receptor agonists as antecedent therapy for ischemic brain injury

Advancing preclinical studies to the nonhuman primate

Frances Bahjat, Keri B. Vartanian, G. Alexander West, Mary Stenzel-Poore

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Antecedent therapy for ischemic brain injury has the potential to protect a large, high-risk patient population from the devastating effects of cerebral ischemia associated with cardiac surgery. Substantial evidence has shown that preconditioning with a modestly damaging stimulus induces powerful endogenous neuroprotection. Pharmacological agents that stimulate toll-like receptors (TLRs) induce robust neuroprotective effects as preconditioning stimuli against cerebral ischemia in mouse and nonhuman primate models of stroke. Here we describe the progress of our preclinical development of TLR agonists as antecedent therapy against cerebral ischemic injury. The objective was to discuss studies that begin with in vitro validation in cell cultures to in vivo efficacy studies using mouse and nonhuman primate models of stroke, with particular emphasis on the TLR9 agonist CpG oligonucleotide. We provide an in-depth discussion of our novel rhesus macaque stroke model and cover the progress we have made in therapeutic testing and evaluation in these animals. These studies represent a logical path for the

Original languageEnglish (US)
Title of host publicationTranslational Stroke Research
Subtitle of host publicationFrom Target Selection to Clinical Trials
PublisherSpringer New York
Pages205-230
Number of pages26
ISBN (Electronic)9781441995308
ISBN (Print)9781441995292
DOIs
StatePublished - Jan 1 2012

Fingerprint

Toll-Like Receptors
Brain Injuries
Primates
Stroke
Brain Ischemia
Neuroprotective Agents
Macaca mulatta
Oligonucleotides
Thoracic Surgery
Therapeutics
Cell Culture Techniques
Pharmacology
Wounds and Injuries
Population

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Bahjat, F., Vartanian, K. B., West, G. A., & Stenzel-Poore, M. (2012). Toll-like receptor agonists as antecedent therapy for ischemic brain injury: Advancing preclinical studies to the nonhuman primate. In Translational Stroke Research: From Target Selection to Clinical Trials (pp. 205-230). Springer New York. https://doi.org/10.1007/978-1-4419-9530-8_10

Toll-like receptor agonists as antecedent therapy for ischemic brain injury : Advancing preclinical studies to the nonhuman primate. / Bahjat, Frances; Vartanian, Keri B.; West, G. Alexander; Stenzel-Poore, Mary.

Translational Stroke Research: From Target Selection to Clinical Trials. Springer New York, 2012. p. 205-230.

Research output: Chapter in Book/Report/Conference proceedingChapter

Bahjat, F, Vartanian, KB, West, GA & Stenzel-Poore, M 2012, Toll-like receptor agonists as antecedent therapy for ischemic brain injury: Advancing preclinical studies to the nonhuman primate. in Translational Stroke Research: From Target Selection to Clinical Trials. Springer New York, pp. 205-230. https://doi.org/10.1007/978-1-4419-9530-8_10
Bahjat F, Vartanian KB, West GA, Stenzel-Poore M. Toll-like receptor agonists as antecedent therapy for ischemic brain injury: Advancing preclinical studies to the nonhuman primate. In Translational Stroke Research: From Target Selection to Clinical Trials. Springer New York. 2012. p. 205-230 https://doi.org/10.1007/978-1-4419-9530-8_10
Bahjat, Frances ; Vartanian, Keri B. ; West, G. Alexander ; Stenzel-Poore, Mary. / Toll-like receptor agonists as antecedent therapy for ischemic brain injury : Advancing preclinical studies to the nonhuman primate. Translational Stroke Research: From Target Selection to Clinical Trials. Springer New York, 2012. pp. 205-230
@inbook{634920119ddf4558af2b6de677bc6c70,
title = "Toll-like receptor agonists as antecedent therapy for ischemic brain injury: Advancing preclinical studies to the nonhuman primate",
abstract = "Antecedent therapy for ischemic brain injury has the potential to protect a large, high-risk patient population from the devastating effects of cerebral ischemia associated with cardiac surgery. Substantial evidence has shown that preconditioning with a modestly damaging stimulus induces powerful endogenous neuroprotection. Pharmacological agents that stimulate toll-like receptors (TLRs) induce robust neuroprotective effects as preconditioning stimuli against cerebral ischemia in mouse and nonhuman primate models of stroke. Here we describe the progress of our preclinical development of TLR agonists as antecedent therapy against cerebral ischemic injury. The objective was to discuss studies that begin with in vitro validation in cell cultures to in vivo efficacy studies using mouse and nonhuman primate models of stroke, with particular emphasis on the TLR9 agonist CpG oligonucleotide. We provide an in-depth discussion of our novel rhesus macaque stroke model and cover the progress we have made in therapeutic testing and evaluation in these animals. These studies represent a logical path for the",
author = "Frances Bahjat and Vartanian, {Keri B.} and West, {G. Alexander} and Mary Stenzel-Poore",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/978-1-4419-9530-8_10",
language = "English (US)",
isbn = "9781441995292",
pages = "205--230",
booktitle = "Translational Stroke Research",
publisher = "Springer New York",

}

TY - CHAP

T1 - Toll-like receptor agonists as antecedent therapy for ischemic brain injury

T2 - Advancing preclinical studies to the nonhuman primate

AU - Bahjat, Frances

AU - Vartanian, Keri B.

AU - West, G. Alexander

AU - Stenzel-Poore, Mary

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Antecedent therapy for ischemic brain injury has the potential to protect a large, high-risk patient population from the devastating effects of cerebral ischemia associated with cardiac surgery. Substantial evidence has shown that preconditioning with a modestly damaging stimulus induces powerful endogenous neuroprotection. Pharmacological agents that stimulate toll-like receptors (TLRs) induce robust neuroprotective effects as preconditioning stimuli against cerebral ischemia in mouse and nonhuman primate models of stroke. Here we describe the progress of our preclinical development of TLR agonists as antecedent therapy against cerebral ischemic injury. The objective was to discuss studies that begin with in vitro validation in cell cultures to in vivo efficacy studies using mouse and nonhuman primate models of stroke, with particular emphasis on the TLR9 agonist CpG oligonucleotide. We provide an in-depth discussion of our novel rhesus macaque stroke model and cover the progress we have made in therapeutic testing and evaluation in these animals. These studies represent a logical path for the

AB - Antecedent therapy for ischemic brain injury has the potential to protect a large, high-risk patient population from the devastating effects of cerebral ischemia associated with cardiac surgery. Substantial evidence has shown that preconditioning with a modestly damaging stimulus induces powerful endogenous neuroprotection. Pharmacological agents that stimulate toll-like receptors (TLRs) induce robust neuroprotective effects as preconditioning stimuli against cerebral ischemia in mouse and nonhuman primate models of stroke. Here we describe the progress of our preclinical development of TLR agonists as antecedent therapy against cerebral ischemic injury. The objective was to discuss studies that begin with in vitro validation in cell cultures to in vivo efficacy studies using mouse and nonhuman primate models of stroke, with particular emphasis on the TLR9 agonist CpG oligonucleotide. We provide an in-depth discussion of our novel rhesus macaque stroke model and cover the progress we have made in therapeutic testing and evaluation in these animals. These studies represent a logical path for the

UR - http://www.scopus.com/inward/record.url?scp=85027306307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027306307&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-9530-8_10

DO - 10.1007/978-1-4419-9530-8_10

M3 - Chapter

SN - 9781441995292

SP - 205

EP - 230

BT - Translational Stroke Research

PB - Springer New York

ER -